Skip to main content
ARTELO BIOSCIENCES, INC. logo

ARTELO BIOSCIENCES, INC. — Investor Relations & Filings

Ticker · ARTL ISIN · US04301G7060 US Manufacturing
Open in API
Filings indexed 425 across all filing types
Latest filing 2026-06-05 Proxy Solicitation & In…
Country US United States of America
Listing US ARTL

About ARTELO BIOSCIENCES, INC.

https://artelobio.com/

Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutics. The company's scientific approach is centered on modifying lipid-signaling pathways, particularly by modulating the endocannabinoid system. Its primary therapeutic focus is on developing improved treatments for patients with cancer and other serious diseases. Artelo is advancing a diverse portfolio of drug candidates through its development pipeline to address unmet medical needs.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement
2026-06-05 English
DEF 14A
Proxy Solicitation & Information Statement
2026-06-05 English
ARS
Annual Report
2026-06-05 English
FORM 8-K
Regulatory Filings
2026-05-27 English
424B5
Share Issue/Capital Change Classification · 92% confidence The document is a full prospectus supplement (Form 424B5) and base prospectus for an at-the-market offering of up to $6.53 million of common stock, including detailed terms of the share issuance, plan of distribution, use of proceeds, risk factors, and SEC registration details. It is not merely a report publication announcement or an officer certification, nor an earnings release or annual report. It concerns the company raising capital by issuing new shares. This falls squarely under “Share Issue/Capital Change,” which covers announcements and documentation of new share issuances and related capital structure changes.
2026-05-26 English
FORM 424B5
Capital/Financing Update Classification · 82% confidence The document is a Form 424B5 prospectus supplement amending an existing at-the-market equity offering, reporting the number of shares sold, gross proceeds raised, and termination of the Sales Agreement. This constitutes a financing update regarding the company’s capital-raising activities rather than an annual or interim report or simple announcement of report publication. Therefore, it falls under "Capital/Financing Update" (Code: CAP).
2026-05-18 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.